Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study
Background: Establishing correlates of protection often requires large cohorts. A rapid and adaptable case-control study design can be used to identify antibody correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in serum and saliva. Methods: We de...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2024
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Descargar el archivo Enlace permanente (DOI o Handle) Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508871526154240 |
|---|---|
| author | Léopold Beeker Thomas Obadia Emma Bloch Laura García Marek Fol Tiffany Charmet Laurence Arowas Rémy Artus Olivia Chény Dorian Cheval Yanis Dahoumane Maurine Delhaye Delal Ergen Mariem Essaidani Christine Fanaud Sandrine Fernandes Pellerin Nathalie Jolly Hélène Laude Emmanuel Roux Marine Samson Linda Sangari Marie-Noëlle Ungeheuer Sophie Vacant Ayla Zayoud Françoise Donnadieu Stéphane Pelleau Simon Galmiche Arnaud Fontanet Michaël White |
| author_browse | Arnaud Fontanet Ayla Zayoud Christine Fanaud Delal Ergen Dorian Cheval Emma Bloch Emmanuel Roux Françoise Donnadieu Hélène Laude Laura García Laurence Arowas Linda Sangari Léopold Beeker Marek Fol Marie-Noëlle Ungeheuer Mariem Essaidani Marine Samson Maurine Delhaye Michaël White Nathalie Jolly Olivia Chény Rémy Artus Sandrine Fernandes Pellerin Simon Galmiche Sophie Vacant Stéphane Pelleau Thomas Obadia Tiffany Charmet Yanis Dahoumane |
| author_facet | Léopold Beeker Thomas Obadia Emma Bloch Laura García Marek Fol Tiffany Charmet Laurence Arowas Rémy Artus Olivia Chény Dorian Cheval Yanis Dahoumane Maurine Delhaye Delal Ergen Mariem Essaidani Christine Fanaud Sandrine Fernandes Pellerin Nathalie Jolly Hélène Laude Emmanuel Roux Marine Samson Linda Sangari Marie-Noëlle Ungeheuer Sophie Vacant Ayla Zayoud Françoise Donnadieu Stéphane Pelleau Simon Galmiche Arnaud Fontanet Michaël White |
| author_sort | Léopold Beeker |
| collection | Producción científica |
| description | Background: Establishing correlates of protection often requires large cohorts. A rapid and adaptable case-control study design can be used to identify antibody correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in serum and saliva. Methods: We designed a case-control study to compare antibody levels between cases of SARS-CoV-2 infection within 5 days of symptom onset and uninfected controls. Controls were matched on age, number of coronavirus disease 2019 vaccine doses, time since last dose, and past episodes of infection. We quantified anti-SARS-CoV-2 and seasonal coronavirus immunoglobulin (Ig) G in serum and saliva at inclusion, 1 month, and 6 months. Results: We included 90 cases and 62 controls between February and September 2022. A boost and decay pattern of serum antibodies was observed in cases at 1 and 6 months, respectively, but not in controls. Anti-SARS-CoV-2 antibody levels were significantly higher in controls at inclusion both in serum (particularly antinucleocapsid IgG: 4.14 times higher compared with cases; 95% CI, 2.46-6.96) and saliva (particularly antispike for Delta variant IgG: 4.89 times higher compared with cases; 95% CI, 2.91-9.89). Saliva antibodies generally outperformed serum antibodies for case/control differentiation. Conclusions: In this case-control study, we provided evidence of correlates of protection of anti-SARS-CoV-2 IgG in saliva and serum, with saliva antibodies often outperforming serum. The finding that antibodies in saliva are a better correlate of protection than antibodies in serum may inform vaccine development by highlighting the importance of robust induction of mucosal immune responses. This study design may be used during future epidemics for the prompt assessment of correlates of protection. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/1732 |
| institution | UPeU |
| language | English |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/17322026-10-30T16:16:37ZCorrelates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control StudyLéopold BeekerThomas ObadiaEmma BlochLaura GarcíaMarek FolTiffany CharmetLaurence ArowasRémy ArtusOlivia ChényDorian ChevalYanis DahoumaneMaurine DelhayeDelal ErgenMariem EssaidaniChristine FanaudSandrine Fernandes PellerinNathalie JollyHélène LaudeEmmanuel RouxMarine SamsonLinda SangariMarie-Noëlle UngeheuerSophie VacantAyla ZayoudFrançoise DonnadieuStéphane PelleauSimon GalmicheArnaud FontanetMichaël WhiteMedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)MedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyInternal medicineOutbreakDiseaseHealth Sciences Medicine Infectious Diseases SARS-CoV-2 detection and testingHealth Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 ResearchHealth Sciences Medicine Infectious Diseases COVID-19 Clinical Research StudiesBackground: Establishing correlates of protection often requires large cohorts. A rapid and adaptable case-control study design can be used to identify antibody correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in serum and saliva. Methods: We designed a case-control study to compare antibody levels between cases of SARS-CoV-2 infection within 5 days of symptom onset and uninfected controls. Controls were matched on age, number of coronavirus disease 2019 vaccine doses, time since last dose, and past episodes of infection. We quantified anti-SARS-CoV-2 and seasonal coronavirus immunoglobulin (Ig) G in serum and saliva at inclusion, 1 month, and 6 months. Results: We included 90 cases and 62 controls between February and September 2022. A boost and decay pattern of serum antibodies was observed in cases at 1 and 6 months, respectively, but not in controls. Anti-SARS-CoV-2 antibody levels were significantly higher in controls at inclusion both in serum (particularly antinucleocapsid IgG: 4.14 times higher compared with cases; 95% CI, 2.46-6.96) and saliva (particularly antispike for Delta variant IgG: 4.89 times higher compared with cases; 95% CI, 2.91-9.89). Saliva antibodies generally outperformed serum antibodies for case/control differentiation. Conclusions: In this case-control study, we provided evidence of correlates of protection of anti-SARS-CoV-2 IgG in saliva and serum, with saliva antibodies often outperforming serum. The finding that antibodies in saliva are a better correlate of protection than antibodies in serum may inform vaccine development by highlighting the importance of robust induction of mucosal immune responses. This study design may be used during future epidemics for the prompt assessment of correlates of protection.Articlehttps://pubmed.ncbi.nlm.nih.gov/39872812https://academic.oup.com/ofid/article-pdf/12/1/ofaf006/61372708/ofaf006.pdfhttps://doi.org/10.1093/ofid/ofaf00610.1093/ofid/ofaf006https://hdl.handle.net/20.500.15037/1732W4406920647enOpen Forum Infectious Diseases2328-89572024-12-232026-06-13T14:20:04Z2026-06-13T14:20:04Z |
| spellingShingle | Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Infectious disease (medical specialty) Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 detection and testing Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies Léopold Beeker Thomas Obadia Emma Bloch Laura García Marek Fol Tiffany Charmet Laurence Arowas Rémy Artus Olivia Chény Dorian Cheval Yanis Dahoumane Maurine Delhaye Delal Ergen Mariem Essaidani Christine Fanaud Sandrine Fernandes Pellerin Nathalie Jolly Hélène Laude Emmanuel Roux Marine Samson Linda Sangari Marie-Noëlle Ungeheuer Sophie Vacant Ayla Zayoud Françoise Donnadieu Stéphane Pelleau Simon Galmiche Arnaud Fontanet Michaël White Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title | Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title_full | Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title_fullStr | Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title_full_unstemmed | Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title_short | Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study |
| title_sort | correlates of protection against symptomatic covid 19 the corser 5 case control study |
| topic | Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Infectious disease (medical specialty) Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 detection and testing Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies |
| topic_facet | Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Infectious disease (medical specialty) Medicine Coronavirus disease 2019 (COVID-19) 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virology Internal medicine Outbreak Disease Health Sciences Medicine Infectious Diseases SARS-CoV-2 detection and testing Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies |
| url | https://pubmed.ncbi.nlm.nih.gov/39872812 https://academic.oup.com/ofid/article-pdf/12/1/ofaf006/61372708/ofaf006.pdf https://doi.org/10.1093/ofid/ofaf006 https://hdl.handle.net/20.500.15037/1732 |
| work_keys_str_mv | AT leopoldbeeker correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT thomasobadia correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT emmabloch correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT lauragarcia correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT marekfol correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT tiffanycharmet correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT laurencearowas correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT remyartus correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT oliviacheny correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT doriancheval correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT yanisdahoumane correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT maurinedelhaye correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT delalergen correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT mariemessaidani correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT christinefanaud correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT sandrinefernandespellerin correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT nathaliejolly correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT helenelaude correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT emmanuelroux correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT marinesamson correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT lindasangari correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT marienoelleungeheuer correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT sophievacant correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT aylazayoud correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT francoisedonnadieu correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT stephanepelleau correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT simongalmiche correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT arnaudfontanet correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy AT michaelwhite correlatesofprotectionagainstsymptomaticcovid19thecorser5casecontrolstudy |